Active, not recruitingPhase 3NCT02477696

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Acerta Pharma BV
Principal Investigator: Acerta Clinical Trials
1-888-292-9613
Intervention: Acalabrutinib(drug)
Enrollment: 533 enrolled
Eligibility: 18 years · All sexes
Timeline: 2015 – 2028

Study locations (30)

Research Site, Phoenix, Arizona, United States
Research Site, Anaheim, California, United States
Research Site, Berkeley, California, United States
Research Site, Duarte, California, United States
Research Site, La Jolla, California, United States
Research Site, Los Angeles, California, United States
Research Site, Palo Alto, California, United States
Research Site, Santa Rosa, California, United States
Research Site, Jacksonville, Florida, United States
Research Site, Tampa, Florida, United States
Research Site, Athens, Georgia, United States
Research Site, Harvey, Illinois, United States
Research Site, Peoria, Illinois, United States
Research Site, Wichita, Kansas, United States
Research Site, Minneapolis, Minnesota, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02477696 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials